It has been hypothesized that if expression of diabetes-resistant MHC class II alleles on bone marrow-derived cells is sufficient to prevent diabetes, genetic engineering of autologous hematopoietic stem cells could be used to restore expression of diabetes-resistant MHC on bone marrow–derived cells. The gene discussed is HLA-C; the disease is diabetes mellitus.